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 College oAbstract Background: Ischemia modiﬁed albumin (IMA) is an albumin that has an altered bind-
ing capacity to bind metal ions and can be used to detect myocardial ischemia in acute coronary
syndrome (ACS) patients.
Aim of work: To study the IMA level in patients presenting with non-ST segment elevation ACS
and its diagnostic and prognostic value.
Patients and methods: This study was conducted on 50 patients with a mean age of 54.7 ± 9 yrs.
Patients were grouped into group 1: unstable angina (13 patients), group 2: NSTEMI (17 patients),
and group 3: control group. All patients were subjected to routine labs, cardiac biomarkers and pre-
discharge coronary angiography and were followed up for 2 months to detect any major adverse
cardiac event. IMA level was measured upon admission for all patients. All data were statistically
analyzed.
Results: IMA was statistically signiﬁcantly higher in groups 1 and 2 compared to group 3
patients (P value < 0.05). The optimal cutoff value to diagnose ischemic patients was 4 ng/ml.
The mean IMA level was signiﬁcantly cardiac biomarkers including troponin, TIMI risk score
and number of the affected vessels but not correlated with the modiﬁed Gensini score (MGS),
and short term prognosis. The optimal cutoff value for IMA levels to predict poor prognosis
was 9.65 ng/ml.
Conclusion: Serum IMA is a useful marker to rule out non ischemic patients presented with sus-
pected ACS and is signiﬁcantly related to the number of affected vessels.
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Acute coronary syndrome (ACS), is one of the leading causes of
morbidity and mortality worldwide [1]. Many of these patients
have normal or nonspeciﬁc electrocardiographic changes, as
well as normal admission CK–MB and troponin levels. That is10.002
n and hosting by Elsevier B.V.
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ischemia before the occurrence of myocardial necrosis would
be of great value and impact on management of such patients
in chest pain and coronary care units [2]. Ischemia modiﬁed
albumin (IMA), a serum biomarker, is an albumin that has an
altered capacity to bind metal ions such as cobalt (Co), copper
(Cu) and nickel (Ni) in its N-terminus. It is produced and can
bemeasured in the serumduring acute ischemic events [3]. These
changes are presumed to be related to the production of reactive
oxygen species (ROS)during ischemia and reperfusion, hypoxia,
and acidosis. Therefore, IMA can be used to detect myocardial
ischemia in patients presenting with suspected acute coronary
syndrome [4].
Aim of work
To study the IMA level in patients presenting with non-ST
segment elevation acute coronary syndromes and to deter-
mine its diagnostic and prognostic value.
Patients and methods
This study was prospective observational study, conducted
on 50 patients with a mean age of 54.7 ± 9 yrs. Of these
30 patients presented to the critical care department of
Cairo University with typical chest pain of less than 4 h
duration and were diagnosed as having non-ST elevation
acute coronary syndrome during the period of September
2012 to January 2013 were included in the study. Patients
were then segregated according to troponin level into unsta-
ble angina (UA) (gp 1), NSTEMI (gp 2). Another 20 pa-
tients referred to the catheter laboratory for suspected
coronary artery disease and diagnosed as having normal
coronaries served as control (gp 3). All patients gave in-
formed written consents and the protocol was approved
by the local ethical committee and in accordance with the
declaration of Helsinki. All patients were subjected to all
of the following: full history taking, routine general and
systemic examination, twelve-lead ECG, routine laboratory
tests, cardiac biomarkers including qualitative troponin that
were done upon admission and serially every 8 h for 24 h.
For all patients TIMI risk score was estimated: (age
65 year, three or more risk factors of CAD, known CAD,
ASA use in the past 7 days, Severe angina: two episodes
within 24 h, ST changes > 0.5 mm, and +ve cardiac mar-
ker). If any of the previous items were present it is graded
as one, absent graded as zero with maximum score 7 and
minimum of 0. Standard 2D, M mode, pulsed and color
Doppler using parasternal and apical views echocardio-
graphic examination. For all patients plasma IMA level
was measured upon admission and on the day of coronary
angiography for control group using Uscn, Inc. enzyme-
linked immunosorbent Assay (ELISA).
Material collection and stability
Plasma samples were collected using EDTA or heparin as
an anticoagulant. Samples centrifuged for 15 min at
1000·g at 2–8 C within 30 min of sample collection.
Samples were stored at 20 C to avoid loss of bioactivity
and contamination.Test principle
The microtiter plate provided in this kit has been pre-coated
with a monoclonal antibody speciﬁc to IMA. Standards or
samples were then added to the appropriate microtiter plate
wells with a biotin-conjugated polyclonal antibody prepara-
tion speciﬁc for IMA. Next, Avidin conjugated to horseradish
peroxidase (HRP) was added to each microplate well and incu-
bated. Then a tetramethylbenzidine (TMB) substrate solution
was added to each well. Only those wells that contain IMA,
biotin-conjugated antibody and enzyme-conjugated Avidin
will exhibit a change in color. The enzyme–substrate reaction
was terminated by the addition of a sulfuric acid solution
and the color change was measured spectrophotometrically
at a wavelength of 450 nm ± 10 nm. The concentration of
IMA in the samples was then determined by comparing the
O.D. of the samples to the standard curve.
All patients included in the study were subjected to pre-dis-
charge coronary angiography. Coronary angiogram was
undertaken by the percutaneous trans femoral or trans radial
approach and all images were recorded digitally. Coronary
angiograms were scored visually into a severity score (0–3)
which deﬁned the number of vessels with a luminal stenosis
of 50% (for right, left anterior descending, and circumﬂex
arteries or its main branch). Then the severity and extent of
CAD were graded using a modiﬁed Gensini score (MGS).
The most severe stenosis in each of the three coronaries and
in the left main was graded from 0 to 6; 0 no stenosis; 1,
1–29% stenosis; 2, 30–49% stenosis; 3, 50–69% stenosis; 4,
70–89% stenosis; 5, 90–99%; stenosis 6, 100% occlusion and
summed to yield a score of 0–24 [5]. During hospital stay
and 2 months after discharge, patients were followed to detect
the occurrence of any major adverse cardiac events (MACE):
(1) Recurring myocardial ischemia, translated by the reappear-
ance of angina or acute myocardial infarction (STEMI or
NON STEMI). (2) Left sided heart failure deﬁned by signs
and symptoms of pulmonary congestion, requiring the use of
speciﬁc therapy, such as diuretics, vasodilators, or inotropic
support. (3) Cardiogenic shock deﬁned as systolic blood pres-
sure <90 mm Hg for more than 30 min, requiring the use of
vasopressors or the development of metabolic acidosis. (4)
Arrhythmias requiring pharmacological treatment, electrical
cardioversion or use of pacemaker. (5) Death [6].
All patients were managed according to the latest European
guidelines.
Exclusion criteria
Any patients who had any of the following: age <18 years,
history of recent cerebrovascular accidents within 1 month of
admission, advanced peripheral vascular disease, acute limb
ischemia, recent history of chest trauma, serum creatinine
>1.5 mg/dl, or abnormal albumin level i.e. outside the refer-
ence range of 3.5–5 mg/dl were excluded from the study.
Statistical analysis
Computer software package SPSS 15.0 was used in the analy-
sis. For quantitative variables, mean/median (as a measure of
central tendency), standard deviation/range, minimum, and
maximum (as measures of variability) were presented.
Table 2 IMA level in the studied groups.
Group 1 Group 2 Group 3 P value
13 Patients 17 Patients 20 Patients
IMA level 14.11 ± 16.45 8.70 ± 11.7 3.02 ± 3.47 0.007
Table 3 Comparison between IMA level in ischemic patients
and control groups.
IMA P value
Ischemic patients (30 pts) 10.84 ± 13.78 ng/ml 0.011
Control patients (20 pts) 3.02 ± 3.47 ng/ml
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variables. Mann–Whitney, Kruskal–Wallis and ANOVA tests
were used to estimate differences in quantitative variables. Chi-
square and Fisher’s exact tests were used to estimate differ-
ences in qualitative variables. Correlation to estimate associa-
tion between quantitative variables was presented in the form
of a correlation coefﬁcient and its signiﬁcance. A probability
value (P value) less than 0.05 was considered signiﬁcant. Recei-
ver operating characteristic (ROC) curves were plotted to
determine the best diagnostic and prognostic cut-off values
for IMA.
Results
During the period of September 2012 to January 2013, 30 pa-
tients admitted to the critical care department of Cairo univer-
sity and diagnosed as having non ST elevation acute coronary
syndrome were enrolled and furtherly divided according to the
troponin level into: unstable angina group (gp 1), and NSTE-
MI group (gp 2). Another 20 patients referred to the cath lab-
oratory because of suspected coronary artery disease and their
results revealed normal coronary angiogram served as the con-
trol group (gp3). Patients’ demographic and general character-
istics on admission are shown in Table 1.
As shown in Table 1, all patients in the study groups were
comparable to each other, with no statistically signiﬁcant dif-
ference regarding their demographic and general characteris-
tics data.
IMA level in different studied groups
The IMA level was signiﬁcantly higher in group 1 and group 2
compared to group 3 patients. Moreover, patients in group 1
had higher levels of IMA compared to group 2 Table 2.
Diagnostic ability of IMA
To detect the ability of IMA to diagnose patients presenting
with acute coronary syndrome, all patients in both groups 1
and 2 were compared to patients in the control group. It was
found that IMA levels were signiﬁcantly higher in patients
compared to controls for whom diagnostic angiography re-
vealed normal coronaries (Table 3).
Receiver operator characteristics (ROC) curve was calcu-
lated to detect the diagnostic ability of IMA in patients
presenting with suspected acute coronary syndrome in theTable 1 General characteristics of the study groups (data are expre
Group 1 Gr
13 Patients 17
Age (yrs) 55.15 ± 4.14 56
Gender n (%) 8 (61.5%) M 12
5 (38.5%) F 5 (
Type I DM 2 (15.3%) 4 (
Type II DM 2 (15.3%) 3 (
Hypertension 9 (69.2%) 6 (
Current smoking 4 (30.7%) 6 (
Dyslipidemia 3 (23%) 5 (
+ve Family history 7 (53.8%) 8 (
EF% (on admission) 54.15 ± 7.99 53coronary care unit. The optimal cutoff value was 4 ng/ml,
and this cutoff value had a sensitivity of 71%, speciﬁcity of
63.1%, positive predictive value 75.9% and negative predictive
value 57.1% with diagnostic accuracy of 71.1% (Fig. 1).
IMA level and other cardiac biomarkers
There was a signiﬁcant positive correlation between IMA level,
CK, and CK–MB level of the study patients (Table 4).
Nonetheless, the mean level of IMA was statistically signif-
icantly higher in troponin positive patients compared to tropo-
nin negative patients (P value = 0.026) (Table 5).
IMA level and TIMI risk score
There was a highly statistically signiﬁcant positive correlation
between IMA level and TIMI risk scores of the study patients
(r= 0.442, P= 0.001) (Table 6).
IMA level and angiographic ﬁndings
There was a signiﬁcant positive correlation between IMA level
and number of vessels affected of the studied patients with po-
sitive coronary angiography (patients in groups 1 and 2)
(r= 0.443, P= 0.049) (Table 7).
However, there was no signiﬁcant correlation between IMA
level and degree of vessel stenosis of the study patients using
MGS (r= 0.070, P= 0.714) (Table 8).ssed as mean (±SD) and number (%)).
oup 2 Group 3 P value
Patients 20 Patients
.29 ± 11.46 52.70 ± 5.83 0.53
(70.5%) M 14 (70%) M 0.885
29.5%) F 6 (30%) F
23.5%) 2 (10%) 0.861
17.6%) 2 (10%) 0.917
35.3%) 12 (60%) 0.381
35.3%) 6 (30%) 0.984
29.4%) 6 (30%) 0.959
47.6%) 10 (50%) 0.793
.35 ± 10.42 60.45 ± 9.29 0.910
Table 7 Correlation between IMA level and number of
affected coronary vessels.
Mean ± SD R P value
IMA 11.05 ± 13.96 0.443 0.049
No of vessels aﬀected 1.5 ± 0.57
Table 8 Correlation between IMA level and severity of
coronary artery disease using modiﬁed Gensini score.
Mean ± SD R P value
IMA 11.05 ± 13.96 0.070 0.714
MGS 16.26 ± 13.84
Table 9 Mean IMA level in relation to morbidity of the study
patients.
No. Mean ± SD of IMA level P value
Morbidity No 41 5.74 ± 8.68 0.735
Yes 7 10.12 ± 12.44
Fig. 1 ROC curve to detect diagnostic ability of IMA.
Table 5 IMA level in relation to troponin in the studied
patients.
IMA level (mean ± SD) P value
Troponin ve patients (33 pts) 7.39 ± 11.79 ng/ml 0.026
Troponin +ve patients (17 pts) 8.70 ± 11.70 ng/ml
Table 4 Correlation between IMA, CK, and CK–MB levels.
Mean ± SD R P value
IMA level 7.84 ± 11.65 ng/ml
CK level 346.06 ± 603.43 IU 0.469 0.009
CK–MB level 35.14 ± 49.48 IU 0.455 0.012
Table 6 Correlation between IMA level and TIMI risk score.
Mean ± SD R P value
IMA 7.84 ± 11.65 ng/ml 0.442 0.001
TIMI score of all pts 3.76 ± 1.09
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During the follow-up period (2 months), among 48 patients
who survived, two suffered from benign arrythmia, two suf-
fered from malignant arrythmia, two had recurrent chest pain
and one patient was subjected to surgical revascularization.The mean level of IMA was higher in morbid patients when
compared with the others, but statistically insigniﬁcant (P va-
lue = 0.735) (Table 9).
A receiver operator characteristics (ROC) curve was calcu-
lated for the use of IMA level as a predictor of morbidity and
mortality. The optimal cutoff value for IMA level that could
be used to predict morbidity and mortality was 9.65 ng/ml.
This cutoff value gave a sensitivity of 66.6%, speciﬁcity of
88.6%, positive predictive value of 44.4%, negative predictive
value of 95.1% with an overall accuracy of 86% (Fig. 2).
Discussion
The ability to detect myocardial ischemia before myocardial
necrosis would allow earlier and more accurate management
decisions for patients admitted with suspected acute coronary
syndrome than is currently possible based on serum troponin,
CK–MB, or myoglobin levels, especially in normal ECG pa-
tients. Previous studies have demonstrated that IMA levels
may be elevated and even precede cardiac troponin elevations
in patients with cardiac ischemia [3]. This early prediction by a
biochemical marker of ischemia is important, as it may im-
prove the ability to stratify acute chest pain patients and guide
therapeutic decisions. Thus, the aim of this study was to test
the accuracy of IMA to diagnose non-ST segment elevation
acute coronary syndromes and to determine if the IMA level
correlates with morbidity and mortality. This study showed
that IMA levels were signiﬁcantly higher in ischemic patients
compared to the control group (10.84 ± 13.78 ng/ml vs
3.02 ± 3.47 ng/ml, P value: 0.011) and positively correlated
with other cardiac biomarkers (CK, CK–MB, and qualitative
troponin). Importantly, the IMA level was signiﬁcantly higher
in unstable angina patients compared to non ST-segment ele-
vation patients (14.11 ± 16.45 vs 8.70 ± 11.7 ng/ml, P value:
<0.05), implying that elevation of IMA is related to myocar-
dial ischemia and not related to myocardial necrosis. Sinha
et al. used the albumin cobalt binding (ACB) test to measure
IMA level and reported that the sensitivity of IMA at presen-
tation for an ischemic origin of chest pain was 82%, compared
with 20% of cTnT, indicating that elevation of IMA was re-
lated to myocardial ischemia rather than myocardial injury
[4]. Bar-Or et al. reported the same ﬁndings, as they found that
IMA elevation occurred within minutes of myocardial
ischemia and remained for several hours later before the devel-
opment of myocardial necrosis, as evidenced by normal CK,
CK–MB, myoglobin and troponin levels [7]. To the best of
our knowledge, none of the previous studies used ELISA tech-
Fig. 2 ROC curve to detect prognostic ability of IMA.
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method to convert units measured by ACB test to nanograms;
the unit used to measure IMA level using ELISA technique. In
2011, Amit et al. reported that there was a signiﬁcant increase
in IMA level in patients with acute ischemic stroke at admis-
sion, 24 h, 48 h and 144 h, respectively, when compared with
controls [8]. Moreover, Turedi et al. reported that IMA level
is signiﬁcantly higher in patients with pulmonary embolism
compared to controls [9] This means that IMA is a sensitive
test to diagnose ischemic events but not speciﬁc to myocardial
ischemia. So it can be used to diagnose acute coronary syn-
dromes only after exclusion of other ischemic conditions. In
the present study a cut-off value of 4 ng/ml had a sensitivity
of 71%, speciﬁcity of 63.1%, positive predictive value 75.9%
and negative predictive value 57.1%. This result indicates that
this cut-off value of IMA may improve our ability to rule out
patients who do not have acute coronary syndrome. In con-
trast, in 2010 Richard Ming-Hui Lin et al. failed to ﬁnd any
diagnostic value for adding IMA level measurement to tropo-
nin measurement in patients presenting with suspected acute
coronary syndrome [10]. The discrepancy between both studies
may be related to the difference of the study population. While
all their studied patients were admitted with suspected ACS,
two-ﬁfth of our studied patients served as control. In this
study, there was a highly statistical signiﬁcant positive correla-
tion between IMA levels and TIMI risk score of the study pa-
tients (r= 0.442, P= 0.001). Also, there was signiﬁcant
positive correlation between IMA levels and the extent of the
coronary artery disease, deﬁned by number of vessels affected
in ischemic patients (r= 0.443, P= 0.049) but not the severity
of the disease as deﬁned by MGS (r= 0.070, P= 0.714). As a
predictor of mortality, IMA at a level of 9.65 ng/ml had a sen-
sitivity of 66.6% and speciﬁcity of 88.6% (PPV 44.4%, NPV
95.1% and diagnostic accuracy of 86%). Although the mean
level of IMA was higher in morbid patients (during the fol-
low-up period) when compared with non-morbid patients, this
difference was statistically insigniﬁcant (P value >0.05).
Contrary to our results, the results published by Bali et al. in
2008 reported that the median IMA level was signiﬁcantly
higher in patients with MACE during hospitalization
(P= 0.007) and at 1 year (P< 0.001) [11]. Yet the lack of this
statistical signiﬁcance in our study could be explained by thesmall sample size and a shorter follow-up period compared
to the study of Bali et al. (2 months vs. 1 year follow-up).Conclusion
Serum IMA is a useful marker to rule out non-ST segment ele-
vation acute coronary syndrome, and segregate UA from
NSTEMI. It correlates well with TIMI score and extent of
CAD, but does not correlate with short-term outcome.Study limitation
In addition to the small number of sample size, the accuracy of
the method used to measure IMA level in our study, ELISA
technique, has not been tested before.
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